[Natalizumab treatment in multiple sclerosis]

Area of Science:

• Neuroimmunology
• Neurodegenerative diseases
• Immunology

Context:

• Multiple sclerosis (MS) is a chronic CNS inflammatory and neurodegenerative disorder.
• The relapse-remitting form is common, necessitating effective therapies.
• Natalizumab (NTZ) is an approved disease-modifying drug in Japan for MS.

Purpose:

• To provide an updated review on natalizumab (NTZ) in multiple sclerosis management.
• To discuss NTZ efficacy in preventing relapses.
• To outline adverse effects, including progressive multifocal leukoencephalopathy (PML).

Summary:

• Natalizumab (NTZ), a monoclonal antibody targeting α4 integrin, prevents lymphocyte adhesion to VCAM-1, thereby inhibiting T-cell infiltration into the CNS.
• This mechanism effectively reduces relapse rates in patients with multiple sclerosis.
• The review addresses treatment considerations post-NTZ discontinuation and body weight-based dosing.

Impact:

• Provides clinicians with current evidence on natalizumab (NTZ) efficacy and safety in multiple sclerosis.
• Informs treatment decisions regarding natalizumab (NTZ) initiation, monitoring, and cessation.
• Highlights the importance of managing adverse events and optimizing dosing strategies for multiple sclerosis patients.